Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab

Brett A. Schroeder*, Karan Kohli, Ryan B. O’Malley, Theresa S. Kim, Robin L. Jones, Robert H. Pierce, Seth M. Pollack

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab'. Together they form a unique fingerprint.

Medicine & Life Sciences